AstraZeneca is to co-promote Abbott’s Trilipix® (fenofibric acid) for the treatment of lipid disorders, which will increase the exposure of Trilipix in the cholesterol market. The two companies filed an NDA for the combination of Trilipix with Crestor® (rosuvastatin), known as Certriad®.